日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Impact of CFTR Modulator Concentrations on Clinical Response in Cystic Fibrosis

CFTR调节剂浓度对囊性纤维化临床反应的影响

Chalamalla, Ashritha R; Baker, Elizabeth; Ryan, Kevin J; Dowell, Alexander; Natt, Jennifer R; Zemanick, Edith T; Konstan, Michael W; Mayer-Hamblett, Nicole; Acosta, Edward P; Guimbellot, Jennifer S

Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad

对囊性纤维化携带者母亲/患病胎儿二元组中母体血液、脐带血、新生儿和母乳中的依来沙卡托/替扎沙卡托/伊伐卡托及其代谢物进行药代动力学评估

Sinkey, Rachel G; Garcia, Bryan; Fowler, Christopher Miles; Krick, Stefanie; Ryan, Kevin J; Acosta, Edward P; Guimbellot, Jennifer S

Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy

评估接受高效调节剂治疗的囊性纤维化成年患者的饮食模式和组成

Bailey, Julianna; Rose, Natalie R; Chalamalla, Ashritha R; Anderson, Justin D; Baker, Elizabeth; Guimbellot, Jennifer S

Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial

伊伐卡托治疗慢性阻塞性肺疾病:一项 II 期随机对照试验的结果

Vijaykumar, Kadambari; Solomon, George M; Guimbellot, Jennifer; Acosta, Edward P; Bhambhavni, Pradeep G; White, Sharon; Kim, Harrison; Raju, S Vamsee; Rasmussen, Lawrence W; Harris, Necole; Liu, Bo; Hathorne, Heather; Rowe, Steven M; Dransfield, Mark T

Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant

肺移植后同时服用他克莫司时,Elexacaftor-tezacaftor-ivacaftor 的药代动力学

Guimbellot, J S; Chalamalla, Ashritha; Baker, Elizabeth; Ryan, K J; Dowell, A; Abouelenein, Saly; Bartlett, L E; Bergeron, J; Turner, G; Acosta, E P; Ramos, K J

Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis

烟草烟雾暴露与囊性纤维化患者长期服用依来卡托/替扎卡托/伊伐卡托的疗效降低有关

Harris, William T; Baker, Elizabeth H; Guimbellot, Jennifer S; Collaco, Joseph M; Schechter, Michael S; Oates, Gabriela R

Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)

G551D 观察性试验 (GOAL) 中烟草烟雾暴露生物标志物与伊伐卡托临床疗效之间的关联

Baker, Elizabeth; Harris, William T; Guimbellot, Jennifer S; Bliton, Kyle; Rowe, Steven M; Raju, S Vamsee; Oates, Gabriela R

Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant

肺移植后患者对依来卡托/替扎卡托/伊伐卡托的看法

Young, Dave; Bartlett, Lauren E; Guimbellot, Jennifer; Milinic, Tijana; Burdis, Nora; Gill, Eliana R; Lease, Erika D; Goss, Christopher H; Kapnadak, Siddhartha G; Ramos, Kathleen J

Evaluating the effects of ivacaftor exposure on Staphylococcus aureus small colony variant development and antibiotic tolerance

评估伊伐卡托暴露对金黄色葡萄球菌小菌落变异株发展和抗生素耐受性的影响

Bollar, Gretchen E; Shaffer, Kendall M; Keith, Johnathan D; Oden, Ashley M; Dowell, Alexander E; Ryan, Kevin J; Acosta, Edward P; Guimbellot, Jennifer S; Kiedrowski, Megan R; Birket, Susan E

Pilot and feasibility study of dietary composition with elexacaftor-tezacaftor-ivacaftor concentrations in people with cystic fibrosis

囊性纤维化患者膳食成分与依来卡托-特扎卡托-伊伐卡托浓度的初步可行性研究

Rose, Natalie R; Bailey, Julianna; Anderson, Justin D; Chalamalla, Ashritha R; Ryan, Kevin J; Acosta, Edward P; Guimbellot, Jennifer S